Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)

Guardado en:

Detalles Bibliográficos
Autores principales:	Dafna Yahav, Benaya Rozen-Zvi, Tiki Mashraki, Alaa Atamna, Haim Ben-Zvi, Erez Bar-Haim, R Rahamimov
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/4d831f93ee1a40e2acc2929792332b0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d831f93ee1a40e2acc2929792332b0c
record_format	dspace
spelling	oai:doaj.org-article:4d831f93ee1a40e2acc2929792332b0c2021-11-25T20:30:04ZImmunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)10.1136/bmjopen-2021-0556112044-6055https://doaj.org/article/4d831f93ee1a40e2acc2929792332b0c2021-10-01T00:00:00Zhttps://bmjopen.bmj.com/content/11/10/e055611.fullhttps://doaj.org/toc/2044-6055Dafna YahavBenaya Rozen-ZviTiki MashrakiAlaa AtamnaHaim Ben-ZviErez Bar-HaimR RahamimovBMJ Publishing GrouparticleMedicineRENBMJ Open, Vol 11, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Dafna Yahav Benaya Rozen-Zvi Tiki Mashraki Alaa Atamna Haim Ben-Zvi Erez Bar-Haim R Rahamimov Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
format	article
author	Dafna Yahav Benaya Rozen-Zvi Tiki Mashraki Alaa Atamna Haim Ben-Zvi Erez Bar-Haim R Rahamimov
author_facet	Dafna Yahav Benaya Rozen-Zvi Tiki Mashraki Alaa Atamna Haim Ben-Zvi Erez Bar-Haim R Rahamimov
author_sort	Dafna Yahav
title	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
title_short	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
title_full	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
title_fullStr	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
title_full_unstemmed	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
title_sort	immunosuppression reduction when administering a booster dose of the bnt162b2 mrna sars-cov-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (became study)
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/4d831f93ee1a40e2acc2929792332b0c
work_keys_str_mv	AT dafnayahav immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy AT benayarozenzvi immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy AT tikimashraki immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy AT alaaatamna immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy AT haimbenzvi immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy AT erezbarhaim immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy AT rrahamimov immunosuppressionreductionwhenadministeringaboosterdoseofthebnt162b2mrnasarscov2vaccineinkidneytransplantrecipientswithoutadequatehumoralresponsefollowingtwovaccinedosesprotocolforarandomisedcontrolledtrialbecamestudy
_version_	1718410028986138624

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)

Ejemplares similares